

Mr. Rodrigo Buenaventura
Head of Secondary Markets
Spanish Stock Exchange Commission
Miguel Ángel, 11, 1st floor
28010 Madrid

RELEVANT FACT

Valencia (Spain), March 8, 2011

Dear Sir,

In accordance with Article 82 of Law 24/1988, 28th July, relative to the regulation of the stock market and related provisions, and following the Relevant Fact sent to your attention on October 7, 2010 regarding the agreement of understanding between Natraceutical and the Brazilian company Bio Group Brazil for the joint-development of Forté Pharma in Brazil as well as a potential acquisition of a majority stake in Natraceutical resulting from the signing of a call option with Natraceutical's parent company Natra, Natraceutical hereby inform you that, after the first four-months period for the execution of the call option, Bio Group Brazil has informed Natra about its decision to reject the call option contract. This decision does not affect however the joint-business project in Brazil, on which both companies are progressing.

Yours faithfully,

Mª José Busutil Santos
Secretary of the Board of Directors
Natraceutical, S.A.

Head Office:

Pl. Xavier Cugat, 2, Ed. D, 2 B
08174 St. Cugat del Vallès, Barcelona
Spain
Tel. (+34) 93 584 81 85
Fax. (+34) 93 584 81 90